Financing ·
BioStem raises $3 million via private placement of common stock and warrants at $4.08 per share
BSEMBioStem Technologies, Inc.
BioStem Technologies raised approximately $3 million in a private placement by selling 735,296 shares of common stock at $4.08 per share, accompanied by Series A and Series B warrants to purchase an equal number of shares at an exercise price of $3.83. The transaction closed on September 30, 2026, with proceeds designated for working capital and general corporate purposes. Additionally, the filing discloses that a $10 million clearance payment due to BioTissue Holdings following FDA approval of its Catalyze product remains unpaid as of late September 2026, with discussions ongoing regarding timing and terms. BioStem Technologies operates in the regenerative medicine industry, developing and commercializing perinatal tissue allograft products.